Australia; NSW; VIC; QLD; SA; WA
An antibody, which helps the immune system to better detect cancer cells, could help people with skin cancer that is at high risk of recurring to live cancer-free longer, according to Australian-led research. The study was in people who had already had surgery or radiotherapy for a type of skin cancer called cutaneous squamous-cell carcinoma, and whose cancer was at a high risk of recurring. The researchers found that people treated with the antibody Cemiplimab for 36 weeks had longer disease-free survival than those who received a placebo.
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
